Catalyst Calendar

Thu, Jul 30, 2026

1 updates

7:00 AM

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.

Presentation / Abstract • Phase 2bicycletherapeutics.com

Thu, May 21, 2026

1 updates

BCYC

5:00 PM

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial

Presentation / Abstract • Phase 2ASCO presentation Fri, May 29, 2026bicycletherapeutics.com